Citi lowered the firm’s price target on Ultragenyx to $130 from $135 and keeps a Buy rating on the shares. The analyst updated biotechnology models post the Q4 results.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RARE:
- Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President
- Ultragenyx appoints Crombz as Chief Medical Officer
- Ultragenyx price target raised to $57 from $50 at Baird
- Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
- Ultragenyx reports Q4 EPS ($2.16), consensus ($2.14)